Cerebral microemboli in patients with antiphospholipid syndrome
Related Experiment Video
Updated: Oct 31, 2026

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
Published on: November 21, 2025
C Specker1, J Rademacher, D Söhngen
1Department of Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany.
Insights
Cerebral microembolic signals (MES) detected via transcranial Doppler ultrasonography are linked to cerebrovascular events in antiphospholipid syndrome (APS). This may aid in assessing stroke risk for APS patients.
Area of Science:
- Neurology
- Rheumatology
- Vascular Medicine
Background:
- Central nervous system (CNS) involvement signifies poor prognosis in Systemic Lupus Erythematosus (SLE).
- Identifying at-risk patients for therapeutic strategies in SLE and Antiphospholipid Syndrome (APS) remains challenging.
- Cerebral microembolic signals (MES) detected by transcranial Doppler ultrasonography (TCD) predict thromboembolic events in carotid artery stenosis.
Purpose of the Study:
- To investigate the utility of MES detection in patients with APS for predicting cerebrovascular events.
- To explore the correlation between MES, antiphospholipid antibodies (aPL), and a history of cerebrovascular ischemia (CVI) in APS patients.
Main Methods:
- Long-term transcranial Doppler ultrasonography (TCD) was used to detect MES in the middle cerebral artery.
- Study population included 46 SLE patients and 5 primary APS (pAPS) patients.
- Historical data on cerebrovascular ischemia (CVI) and antiphospholipid antibody (aPL) status were analyzed.
Main Results:
- MES were detected in 14 out of 16 patients with a history of CVI, versus only 1 in 35 without CVI (P < 0.001).
- MES detection correlated with the titer of aPL.
- The energy distribution of MES in APS patients differed from those with artificial heart valves, resembling those in symptomatic carotid disease.
Conclusions:
- Cerebral MES are detectable in APS patients.
- MES detection correlates with a history of CVI in APS.
- Prospective studies are needed to determine if MES can provide individual risk assessment in APS.
Abstract:
CNS involvement is one of the hallmarks underlying poor prognosis in SLE and for therapeutic strategies it is difficult to assess which patients are at risk. As detectability of cerebral microembolic signals (MES) using long-term transcranial Doppler ultrasonography (TCD) proved to be predictive of past and future thromboembolic events in patients with carotid artery stenosis, we investigated whether MES might be similarly useful in patients with antiphospholipid syndrome (APS). Our study population consisted of 46 SLE patients and five with primary APS (pAPS). Twelve of the 46 patients with SLE, 10 of them with secondary APS (sAPS), and four of five patients with pAPS had a history of cerebrovascular ischaemia (CVI). MES in the middle cerebral artery were detected in 14 of 16 patients with and in one of 35 without CVI (P < 0.001). Antiphospholipid antibodies (aPL) were positive in 12 of 15 patients with and 18 of 36 without MES, and the rate of MES correlated to the titre of aPL. MES from APS patients resembled in their energy distribution those from patients with symptomatic carotid disease and were significantly different from those associated with artificial heart valves. In conclusion, cerebral MES are detectable in APS patients and correlate with a history of CVI. Whether this innovative method may provide individual risk assessment in APS patients has to be addressed in prospective studies.
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Ischemic Stroke l: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Transient Ischemic Attack l: Introduction
Hemorrhagic Stroke l: Introduction
